TG Therapeutics (NASDAQ:TGTX) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of TG Therapeutics (NASDAQ:TGTX) from a hold rating to a buy rating in a research note released on Saturday morning.

A number of other research firms also recently commented on TGTX. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of TG Therapeutics in a research report on Wednesday, October 8th. HC Wainwright assumed coverage on TG Therapeutics in a report on Monday, October 6th. They issued a “buy” rating and a $60.00 price objective for the company. JPMorgan Chase & Co. increased their target price on TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Finally, B. Riley raised TG Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $50.25.

TG Therapeutics Stock Down 3.1%

Shares of TGTX traded down $1.02 during trading hours on Friday, hitting $32.24. The company had a trading volume of 1,762,028 shares, compared to its average volume of 2,355,317. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The stock has a market capitalization of $5.12 billion, a price-to-earnings ratio of 87.14 and a beta of 1.95. TG Therapeutics has a 52-week low of $25.28 and a 52-week high of $46.48. The firm has a fifty day moving average price of $33.91 and a 200-day moving average price of $34.68.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, topping the consensus estimate of $0.24 by $2.19. The firm had revenue of $161.71 million during the quarter, compared to analysts’ expectations of $152.12 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The company’s revenue was up 92.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.02 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that TG Therapeutics will post 0.08 EPS for the current fiscal year.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the firm’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the sale, the director owned 94,061 shares in the company, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.64% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Large investors have recently added to or reduced their stakes in the stock. State Street Corp raised its stake in TG Therapeutics by 2.5% in the 2nd quarter. State Street Corp now owns 7,618,238 shares of the biopharmaceutical company’s stock worth $274,180,000 after acquiring an additional 184,339 shares during the last quarter. Geode Capital Management LLC boosted its position in TG Therapeutics by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 3,490,457 shares of the biopharmaceutical company’s stock valued at $126,033,000 after buying an additional 207,890 shares during the period. Goldman Sachs Group Inc. grew its stake in TG Therapeutics by 21.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock worth $75,683,000 after purchasing an additional 345,059 shares in the last quarter. Hood River Capital Management LLC increased its position in shares of TG Therapeutics by 0.7% in the 2nd quarter. Hood River Capital Management LLC now owns 1,567,506 shares of the biopharmaceutical company’s stock valued at $56,415,000 after purchasing an additional 11,018 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in TG Therapeutics by 1,809.9% during the 1st quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company’s stock worth $47,830,000 after acquiring an additional 1,149,526 shares during the period. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.